**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 78092

**Manuscript Type:** LETTER TO THE EDITOR

**Risk stratification of primary liver cancer**

Tan YW. Risk stratification of PLC

You-Wen Tan

**You-Wen Tan,** Department of Hepatology, The Third Hospital of Zhenjiang Affiliated Jiangsu University, Zhenjiang 212000, Jiangsu Province, China

**Author contributions:** Tan YW wrote, revised the manuscript, and approved the final version to be published.

**Supported by** the Social Development Project of Jiangsu Province, No. BE2020775; the Chinese Federation of Public Health Foundation, No. GWLM202002; and the Social Development Project of Zhenjiang City, No. SH2020032.

**Corresponding author: You-Wen Tan, MD, Chief Doctor, Professor,** Department of Hepatology, The Third Hospital of Zhenjiang Affiliated Jiangsu University, No. 300 Daijiamen, Runzhou Distinct, Zhenjiang 212000, Jiangsu Province, China. tyw915@sina.com

**Received:** June 7, 2022

**Revised:** June 29, 2022

**Accepted:** August 12, 2022

**Published online:** September 16, 2022

**Abstract**

The risk stratification of primary liver cancer (PLC) discussed in a review of viral hepatitis and PLC could lead to misunderstandings by readers. For example, a single study or a small number of studies cannot comprehensively summarize the risk factors of PLC, is not included in the family history of liver cancer, and chronic hepatitis D is listed as a medium risk factor for the development of PLC. Currently, PLC prediction models with good clinical validation values have been applied clinically, such as the Toronto hepatocellular carcinoma risk index, REACH-B model, and PAGE-B model. Therefore, the Chinese, together with several research societies, have formulated the “Guideline for stratified screening and surveillance of primary liver cancer (2020 edition).” This guideline outlines PLC screening in at-risk populations, both in hospitals and communities. It is recommended to stratify the at-risk population into four risk levels: low-, intermediate-, high-, and extremely high-risk. This is highly recommended and applied in clinical practice.

**Key Words:** Risk factors; Model; Primary liver cancer; Hepatocellular carcinoma

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Tan YW. Risk stratification of primary liver cancer. *World J Clin Cases* 2022; 10(26): 9545-9549

**URL:** <https://www.wjgnet.com/2307-8960/full/v10/i26/9545.htm>

**DOI:** https://dx.doi.org/10.12998/wjcc.v10.i26.9545

**Core Tip:** Primary liver cancer (PLC) prediction models with good clinical validation values have been applied clinically, such as the Toronto hepatocellular carcinoma risk index, REACH-B model, and PAGE-B model. Therefore, the Chinese, together with several research societies, have formulated the “Guideline for stratified screening and surveillance of primary liver cancer (2020 edition).” This guideline outlines PLC screening in at-risk populations, both in hospitals and communities. It is recommended to stratify the at-risk population into four risk levels: low-, intermediate-, high-, and extremely high-risk. This is highly recommended and applied in clinical practice.

**TO THE EDITOR**

I have read an article with title: “Viral hepatitis and hepatocellular carcinoma: From molecular pathways to the role of clinical surveillance and antiviral treatment” with great interest[1]. This is a very good systematic review which fully discusses the etiology, risk factors, and pathogenesis of primary liver cancer (PLC). High-, medium-, and low-risk factors of PLC were analyzed. However, the term "risk factors for the development of PLC" in this article could lead to misunderstandings by readers.

First, a single study or a small number of studies cannot comprehensively summarize the risk factors of PLC. Perhaps a meta-analysis is more reasonable. A meta-analysis of chronic hepatitis B hepatocellular carcinoma (HCC) from China included 3165 cases and 10896 controls from 27 studies[2]. The results showed that, from the currently available evidence, Chinese people with a high viral load, not treated with antiviral treatment, with a family history of liver cancer, of male sex, and with chronic hepatitis B virus (HBV) infection are at risk of developing HCC. In another meta-analysis of risk factors for nonalcoholic fatty liver disease (NAFLD) and HCC, 18 studies involving 470,404 patients were included. In NAFLD patients before cirrhosis, the incidence of HCC was 0.03/100 person years. In patients with liver cirrhosis, the incidence rate was 3.78/100 person years[3]. However, it still needs to be noted that the risk factors of PLC that can be seen at present are for a specific disease, and there is still a lack of meta-analysis on the risk factors of all PLC. Many studies have analyzed PLC risk factors. Among them, the studies that have been highly recognized mentioned the Toronto HCC risk index (THRI) which takes into consideration five variables, including age, gender, platelet count, and the cause of liver cirrhosis (0, 0, 36, 54, and 97 for autoimmune liver disease, hepatitis C with sustained virological response [SVR], other liver diseases, fatty hepatitis, untreated chronic hepatitis C or chronic hepatitis B, respectively). A total of 366 points of the THRI model were constructed. The 5-year cumulative incidence rates of HCC in the low- (< 120 points), medium- (120-240 points), and high- (> 240 points) risk groups were 1.2% and 4.5%, 4%, respectively, and 15, and the 10-year cumulative incidence rates of HCC were 3%, 10%, and 32%, respectively[4].

The THRI model was also validated in China. For patients with cirrhosis classified into low-, medium-, and high-risk groups, the 5-year cumulative incidence rates of HCC were 0%, 13%, and 34%, respectively, and the area under the receiver operating characteristic curve (AUC) of the prediction model is 0.707[5]. The significance of the THRI model is that even in patients with liver cirrhosis who are at high risk of HCC, it is still necessary to conduct further risk stratification to distinguish the extremely high-risk population of HCC.

HBV infection is the main cause of HCC. Even without cirrhosis, there is only 6.5% chance of 2%-9.5% of HBV infected individuals to progress to HCC in their lifetime. Some scholars in China have built the REACH-B model with a total of 17 points, including sex, age, alanine aminotransferase (ALT) HBeAg status, and HBV DNA level, aiming at the risk stratification of HBV-infected individuals who have not received antiviral treatment; scores of 0-5, 6-11, and 12-17 are low, medium, and high risk, respectively[6]. The incidence of HCC in the lowest (0) and highest (17) scores within 3, 5, and 10 years is 0.0% and 23.6%, 0.0% and 47.4% and 0.0% and 81.6%, respectively.

HBV remains a risk factor for HCC after antiviral treatment. Based on the 5-year results of oral antiviral treatment with entecavir or tenofovir in 1,815 CHB patients in Europe, the PAGE-B model with three parameters, including age, sex, and platelet count, and a total score of 25 points was constructed to evaluate the risk of HCC in patients with HBV infection after antiviral treatment[7]. According to the score, the patients were divided into three groups: low-risk (0-9 points), medium-risk (10-17 points), and high-risk (18-25 points). The 5-year cumulative incidence of HCC in the low-, moderate-, and high-risk groups was 0%, 0%-4%, and 16%-17%, respectively. The Korean cohort verified that the PAGE-B model was equally effective in Asian populations, and the AUC for 5-year HCC predictive power was 0.77[8].

The PAGE-B team recently added two parameters, age and liver stiffness measurement; thus, the maximum total score is now 15 points and divided into low-risk (< 5 points), medium-risk (6-10 points), and high-risk (> 11 points) levels. The cumulative incidence of HCC in 12 years was 0.0%, 4.0%, 0.0%, and 13.8%. In conclusion, the 5-year cumulative incidence rate of HCC was still 5.5% in patients with chronic HBV infection treated with antiviral therapy, especially those classified in the high-risk group (7%-8.4%). However, the negative predictive rate of HCC in 5 and 12years in the low-risk group is as high as 97.5%-100%[6,8]. In untreated individuals infected with HCV, serum HCV RNA, ALT, and HCV genotype 1b were independent predictors of HCC[9,10].

Risk prediction models have a long history in predicting HCC incidence rate in CHB patients. Currently, approved models are as follows: CU-HCC, GAG-HCC, Page-B, mPAGE-B, REACH-B and mREACH-B[11,12]. A meta-analysis used six models to perform AUC validation on 22 studies published between 2011 and 2020[13]. The AUC values of the six models ranged from 0.715 to 0.778. In the antiviral treatment subgroup, the AUC values of mREACH-B, GAG-HCC and mPAGE-B were 0.785, 0.760 and 0.778, respectively. In the subgroup of liver cirrhosis, the recognition performance of all models is very poor (AUC < 0.7). The clinical application of these models can improve patients’ prognosis and aid them in making informed decisions about treatment. However, these models were derived from different cohorts with or without antiviral treatment and affected by many factors. There are no guidelines for publishing the same standardized guide to predict the risk of HCC among CHB patients[14-16].

Second, among the risk factors, there was no family history of PLC. In the HBV- or HCV-infected population, first-degree relatives with a family history of PLC significantly increased the risk of HCC[17-19]. Scholars in China have followed up 22472 residents and a total of 362268 people / year, and 374 cases of HCC have been detected. HBV patients with a family history of HCC were 2.5 times more likely to develop HCC than those without a family history[19]. A similar cohort of 7933 non-PLC patients and 201 patients with PLC from China also showed that the risk of HCC was 2.76 higher (95% CI, 1.88-4.05) in individuals without HBV infection but with a family history of PLC, but in the population with HBV positive and family history of primary HCC, the risk of HCC was 41.34 (95%CI 23.69-72.12)[17]. Therefore, first-degree relatives infected with HBV and HCV with a family history of liver cancer had a significantly increased risk of HCC in at all stages, which requires special attention[18].

Third, untreated chronic hepatitis D virus infection was classified as a moderate risk factor in the analysis of HCC risk factors, with an OR of 3.9. HDV is a defective virus dependent on HBV infection. Chronic hepatitis D inevitably overlaps with chronic hepatitis B. As described in the article, chronic hepatitis D is considered the most serious form of chronic viral hepatitis, leading to rapid progression of liver cirrhosis and higher mortality. More than 10% of patients infected with chronic hepatitis D virus develop cirrhosis within 5 years of infection, and more than 80% of patients suffer from liver cirrhosis decompensation within 30 years[20]. Recent cohort studies have found that compared to patients with a single HBV infection, the risk of patients with HDV infection is nine times higher, although it is generally believed that HDV does not represent a major risk factor for the development of HCC[21,22]. In addition, persistent hepatitis D virus replication has been a risk factor for liver disease progression to cirrhosis and HCC[23]. A European study on the collaborative action of viral hepatitis showed that the incidence of HCC in patients with anti-hepatitis D virus-positive cirrhosis increased by 3.2 times compared with those with negative hepatitis[21]. Other recent studies have shown that patients with HDV/HBV co-infection have an increased risk of HCC compared to patients with HBV infection alone (adjusted HR = 9.30)[24]. A large study estimated that the risk of HCC in patients with chronic hepatitis D virus infection (RR = 3.9) was significantly higher than that in patients with a single HBV infection[25].

Therefore, the Chinese, together with several research societies have formulated the “Guideline for stratified screening and surveillance of primary liver cancer (2020 edition)”[26]. China has a high incidence of PLC, and chronic HBV infection is still the greatest risk factor for HCC. According to the high-risk factors, the guidelines for screening at-risk populations were divided into low-, intermediate-, high-, and extremely high-risk groups (Table 1) and propose monitoring and timing based on ultrasound findings and alpha fetoprotein level. Abdominal ultrasonography combined with serum alpha-fetoprotein examination (routine surveillance) is recommended every 6 mo for patients at high risk of PLC. Routine surveillance every 3 mo and enhanced computer tomography/ magnetic resonance imaging examination every 6-12 mo are recommended for patients at an extremely high risk of PLC. The surveillance interval can be extended every 1 year or longer for those with low-risk or intermediate-risk PLC because their annual incidence of PLC is very low. However, the cost-effectiveness of these recommendations remains to be evaluated. We believe that the stratified analysis of risk factors and screening recommendations for PLC in China can be successfully implemented by doctors to aid the early diagnosis and treatment of PLC. Of course, large sample verification and observation are required.

**REFERENCES**

1 **Stella L,** Santopaolo F, Gasbarrini A, Pompili M, Ponziani FR. Viral hepatitis and hepatocellular carcinoma: From molecular pathways to the role of clinical surveillance and antiviral treatment. *World J Gastroenterol* 2022; **28**: 2251-2281 [PMID: 35800182 DOI: 10.3748/wjg.v28.i21.2251]

2 **Lyu X**, Liu K, Chen Y, Wang Z, Yao J, Cai G, Jiang Z, Wang Z, Jiang J, Gu H. Analysis of Risk Factors Associated with the Development of Hepatocellular Carcinoma in Chronic HBV-Infected Chinese: A Meta-Analysis. *Int J Environ Res Public Health* 2016; **13** [PMID: 27322300 DOI: 10.3390/ijerph13060604]

3 **Orci LA**, Sanduzzi-Zamparelli M, Caballol B, Sapena V, Colucci N, Torres F, Bruix J, Reig M, Toso C. Incidence of Hepatocellular Carcinoma in Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-analysis, and Meta-regression. *Clin Gastroenterol Hepatol* 2022; **20**: 283-292.e10 [PMID: 33965578 DOI: 10.1016/j.cgh.2021.05.002]

4 **Sharma SA**, Kowgier M, Hansen BE, Brouwer WP, Maan R, Wong D, Shah H, Khalili K, Yim C, Heathcote EJ, Janssen HLA, Sherman M, Hirschfield GM, Feld JJ. Toronto HCC risk index: A validated scoring system to predict 10-year risk of HCC in patients with cirrhosis. *J Hepatol* 2017 [PMID: 28844936 DOI: 10.1016/j.jhep.2017.07.033]

5 **Zhang H**, Zhu J, Xi L, Xu C, Wu A. Validation of the Toronto hepatocellular carcinoma risk index for patients with cirrhosis in China: a retrospective cohort study. *World J Surg Oncol* 2019; **17**: 75 [PMID: 31039803 DOI: 10.1186/s12957-019-1619-3]

6 **Yang HI**, Yuen MF, Chan HL, Han KH, Chen PJ, Kim DY, Ahn SH, Chen CJ, Wong VW, Seto WK; REACH-B Working Group. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score. *Lancet Oncol* 2011; **12**: 568-574 [PMID: 21497551 DOI: 10.1016/S1470-2045(11)70077-8]

7 **Papatheodoridis G**, Dalekos G, Sypsa V, Yurdaydin C, Buti M, Goulis J, Calleja JL, Chi H, Manolakopoulos S, Mangia G, Gatselis N, Keskin O, Savvidou S, de la Revilla J, Hansen BE, Vlachogiannakos I, Galanis K, Idilman R, Colombo M, Esteban R, Janssen HL, Lampertico P. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. *J Hepatol* 2016; **64**: 800-806 [PMID: 26678008 DOI: 10.1016/j.jhep.2015.11.035]

8 **Yip TC**, Wong GL, Wong VW, Tse YK, Liang LY, Hui VW, Lee HW, Lui GC, Chan HL. Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B. *J Hepatol* 2020; **72**: 847-854 [PMID: 31857194 DOI: 10.1016/j.jhep.2019.12.005]

9 **Papatheodoridis GV**, Sypsa V, Dalekos GN, Yurdaydin C, Van Boemmel F, Buti M, Calleja JL, Chi H, Goulis J, Manolakopoulos S, Loglio A, Voulgaris T, Gatselis N, Keskin O, Veelken R, Lopez-Gomez M, Hansen BE, Savvidou S, Kourikou A, Vlachogiannakos J, Galanis K, Idilman R, Esteban R, Janssen HLA, Berg T, Lampertico P. Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. *J Hepatol* 2020; **72**: 1088-1096 [PMID: 31981727 DOI: 10.1016/j.jhep.2020.01.007]

10 **Raimondi S**, Bruno S, Mondelli MU, Maisonneuve P. Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. *J Hepatol* 2009; **50**: 1142-1154 [PMID: 19395111 DOI: 10.1016/j.jhep.2009.01.019]

11 **Wong VW**, Chan SL, Mo F, Chan TC, Loong HH, Wong GL, Lui YY, Chan AT, Sung JJ, Yeo W, Chan HL, Mok TS. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. *J Clin Oncol* 2010; **28**: 1660-1665 [PMID: 20194845 DOI: 10.1200/JCO.2009.26.2675]

12 **Manne V**, Gochanour E, Kowdley KV. Current perspectives into the evaluation and management of hepatitis B: a review. *Hepatobiliary Surg Nutr* 2019; **8**: 361-369 [PMID: 31489305 DOI: 10.21037/hbsn.2019.02.09]

13 **Yang L**, Wang Q, Cui T, Huang J, Jin H. Reporting and Performance of Hepatocellular Carcinoma Risk Prediction Models: Based on TRIPOD Statement and Meta-Analysis. *Can J Gastroenterol Hepatol* 2021; **2021**: 9996358 [PMID: 34513751 DOI: 10.1155/2021/9996358]

14 **Terrault NA**, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr, Bzowej NH, Wong JB. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. *Hepatology* 2018; **67**: 1560-1599 [PMID: 29405329 DOI: 10.1002/hep.29800]

15 **Korean Association for the Study of the Liver.**. KASL clinical practice guidelines: management of chronic hepatitis B. *Clin Mol Hepatol* 2016; **22**: 18-75 [PMID: 27044762 DOI: 10.3350/cmh.2016.22.1.18]

16 **European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu.**; European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. *J Hepatol* 2017; **67**: 370-398 [PMID: 28427875 DOI: 10.1016/j.jhep.2017.03.021]

17 **Liu X**, Baecker A, Wu M, Zhou JY, Yang J, Han RQ, Wang PH, Jin ZY, Liu AM, Gu X, Zhang XF, Wang XS, Su M, Hu X, Sun Z, Li G, Fu A, Jung SY, Mu L, He N, Li L, Zhao JK, Zhang ZF. Family history of liver cancer may modify the association between HBV infection and liver cancer in a Chinese population. *Liver Int* 2019; **39**: 1490-1503 [PMID: 31228882 DOI: 10.1111/Liv.14182]

18 **Turati F**, Edefonti V, Talamini R, Ferraroni M, Malvezzi M, Bravi F, Franceschi S, Montella M, Polesel J, Zucchetto A, La Vecchia C, Negri E, Decarli A. Family history of liver cancer and hepatocellular carcinoma. *Hepatology* 2012; **55**: 1416-1425 [PMID: 22095619 DOI: 10.1002/hep.24794]

19 **Loomba R**, Liu J, Yang HI, Lee MH, Lu SN, Wang LY, Iloeje UH, You SL, Brenner D, Chen CJ; REVEAL-HBV Study Group. Synergistic effects of family history of hepatocellular carcinoma and hepatitis B virus infection on risk for incident hepatocellular carcinoma. *Clin Gastroenterol Hepatol* 2013; **11**: 1636-45.e1-3 [PMID: 23669307 DOI: 10.1016/j.cgh.2013.04.043]

20 **Farci P**, Niro GA, Zamboni F, Diaz G. Hepatitis D Virus and Hepatocellular Carcinoma. *Viruses* 2021; **13** [PMID: 34064419 DOI: 10.3390/v13050830]

21 **Fattovich G**, Giustina G, Christensen E, Pantalena M, Zagni I, Realdi G, Schalm SW. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). *Gut* 2000; **46**: 420-426 [PMID: 10673308 DOI: 10.1136/gut.46.3.420]

22 **Ji J**, Sundquist K, Sundquist J. A population-based study of hepatitis D virus as potential risk factor for hepatocellular carcinoma. *J Natl Cancer Inst* 2012; **104**: 790-792 [PMID: 22423008 DOI: 10.1093/jnci/djs168]

23 **Romeo R**, Foglieni B, Casazza G, Spreafico M, Colombo M, Prati D. High serum levels of HDV RNA are predictors of cirrhosis and liver cancer in patients with chronic hepatitis delta. *PLoS One* 2014; **9**: e92062 [PMID: 24658127 DOI: 10.1371/journal.pone.0092062]

24 **Amougou MA**, Noah DN, Moundipa PF, Pineau P, Njouom R. A prominent role of Hepatitis D Virus in liver cancers documented in Central Africa. *BMC Infect Dis* 2016; **16**: 647 [PMID: 27821080 DOI: 10.1186/s12879-016-1992-2]

25 **Ioannou GN**, Beste LA, Green PK, Singal AG, Tapper EB, Waljee AK, Sterling RK, Feld JJ, KaPLCn DE, Taddei TH, Berry K. Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores. *Gastroenterology* 2019; **157**: 1264-1278.e4 [PMID: 31356807 DOI: 10.1053/j.gastro.2019.07.033]

26 **Professional Committee for Prevention and Control of Hepatobiliary and Pancreatic Diseases of Chinese Preventive Medicine Association;.**; Professional Committee for Hepatology, Chinese Research Hospital Association;; Chinese Society of Hepatology, Chinese Medical Association;; Prevention of Infection Related Cancer (PIRCA) Group, Specialist Committee of Cancer Prevention and Control of Chinese Preventive Medicine Association. [Guideline for stratified screening and surveillance of primary liver cancer(2020 Edition)]. *Zhonghua Gan Zang Bing Za Zhi* 2021; **29**: 25-40 [PMID: 33541021 DOI: 10.3760/cma.j.cn112152-20201109-00970]

**Footnotes**

**Conflict-of-interest statement:** All authors have no conflict of interest related to the manuscript.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** June 7, 2022

**First decision:** June 27, 2022

**Article in press:** August 12, 2022

**Specialty type:** Medicine, research and experimental

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Byeon H, South Korea; Feizi A, Iran **S-Editor:** Wang LL **L-Editor:** A **P-Editor:** Wang LL

**Table 1 Identification and stratification patients with high risk for liver cancer**

|  |  |  |
| --- | --- | --- |
| **Estimated annual incidence of HCC (%)** | **Distinguishing feature** | **Risk stratification model of liver cancer** |
| Low risk of liver cancer (< 1) | (1) HBV infected patients in immune tolerance period; (2) HBV or HCV related chronic hepatitis with SVR acquired by antiviral therapy; and (3) ALT, normal PLCtelet, non viral liver disease | HBsAg positive, REACH-B score ≥ 5 (no antiviral treatment), or PAGE-B score ≤ 9 |
| Moderate risk of liver cancer (1-3) | (1) HBV or HCV related chronic hepatitis of LLV without antiviral treatment or after antiviral treatment, aged < 40 yr; HBV or HCV related cirrhosis with SVR obtained by antiviral therapy; and (2) non viral cirrhosis with normal ALT or chronic non viral hepatitis with abnormal ALT | (1) HBsAg positive, REACH-B score 6-11 (no antiviral treatment) or PAGE-B score 10-17; and (2) THRI score of cirrhotic patients ≤ 240 |
| High risk of liver cancer (> 3 and < 6) | (1) HBV or HCV related cirrhosis of LLV without or after antiviral treatment; (2) non-viral cirrhosis patients with diabetes or family history of liver cancer with first-degree relatives (B1); and (3) men, age > 40 yr old; women, age > 50 yr; No antiviral therapy for HBV/HCV related chronic hepatitis | (1) HBsAg positive, REACH-B score > 12 (no antiviral treatment) or PAGE-B score ≤ 18; and (2) THRI score of cirrhotic patients > 240 |
| Extremely high risk for liver cancer (> 6) | (1) hepatic nodule (1-2 cm) in abdominal US examination or LGDN and HGDN in pathology; (2) HBV and HCV related cirrhotic nodules (< 1 cm); and (3) synergistic risk factors such as no antiviral treatment, HBV or HCV related liver cirrhosis with diabetes or family history of liver cancer in first-degree relatives after treatment | \_ |

ALT: Alanine aminotransferase; HCC: Hepatocellular carcinoma; SVR: Sustained virological response; THRI: Toronto hepatocellular carcinoma risk index.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**